ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1952

The Effect of CXCL10 Blockade in C Protein-Induced Myositis

Jinhyun Kim1, Jiyong Choi2, Sung Hae Chang3, Ki Chul Shin4, Sung-Hye Park5, Hye Won Kim6, Hye Jin Oh4, Myeong Jae Yoon7, Bong Seung Ku8, Eun Young Lee6, Eun Bong Lee3, Hiroshi Kawachi9, Hitoshi Kohsaka10 and Yeong Wook Song11, 1Department of Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 4Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, 5Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 7Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, 8Rheumatology, Department of Internal Medicine, School of Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, South Korea, 9Department of Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 10Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: CXCL10 (also called interferon-γ-inducible protein 10 [IP-10]) is a chemokine that plays a critical role in the infiltration of T cell in autoimmune disease such as RA and SLE. CXCL10 is reported to be expressed in muscle tissue of polymyositis, thus we investigated the role of CXCL10 and the effect of CXCL10 blockade in C protein-induced myositis, an animal model of polymyositis.

Methods: C protein-induced myositis model was induced with human skeletal C protein fragment in 8-week-old female C57BL/6 mice. Immunohistochemistry was performed to detect CXCL10 and CXCR3, its receptor in muscle tissue. CXCR3 in mouse splenocyte was investigated by flow cytometry. Migration assay of mouse splenocyte was performed with 5 μm pore transwell system. Mice with C protein-induced myositis were treated with anti-CXCL10 antibody or control IgG 8 days after the induction of myositis and the inflammation in muscle tissue was assessed 3 week after the induction.

Results: Immunohistochemistry showed the expression of CXCL10 and CXCR3 in the muscle of C protein-induced myositis. Flow cytometry demonstrated increased CXCR3+CD4+ T cells (normal mice, 14.14%±1.09% vs. C protein-induced myositis, 37.50%±5.63%) and CXCR3+CD8+ T cells (normal mice, 35.55±2.41% vs. C protein-induced myositis, 79.00%±0.89%) in C protein-induced myositis. Migration of splenocyte was increased in response to CXCL10 (chemotactic index=1.91±0.45). Treatment with anti-CXCL10 antibody (n=10) showed less inflammation score in muscles than treatment with control IgG (n=10; median [range], anti IP-10, 0.75 [0.25-2.00] vs. control IgG, 1.43 [1.125-4.25], p=0.045).

Conclusion: CXCL10 was expressed in the inflammation of C protein-induced myositis model and its blockade suppressed inflammation in muscle.


Disclosure:

J. Kim,
None;

J. Choi,
None;

S. H. Chang,
None;

K. C. Shin,
None;

S. H. Park,
None;

H. W. Kim,
None;

H. J. Oh,
None;

M. J. Yoon,
None;

B. S. Ku,
None;

E. Y. Lee,
None;

E. B. Lee,
None;

H. Kawachi,
None;

H. Kohsaka,

Chugai Pharma, Ajinomoto Pharma & Teijin Parma,

5;

Y. W. Song,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-cxcl10-blockade-in-c-protein-induced-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology